Showing 6141-6150 of 8555 results for "".
- Paradigm Shift: Can Harnessing the Power of Healthy Cells Prevent Skin Cancer?https://practicaldermatology.com/news/paradigm-switch-can-harnessing-the-power-of-healthy-cells-prevent-skin-cancer/2461803/Do simple wounds or surgery increase skin cancer risks by expanding mutated cells? No, according to a new study by researchers at Yale and the Karolinska Institute in Sweden. Rather than promoting mutant cell growth, injury promotes healthy-cell expansion which keeps mutated cell growth
- Osteopontin Potently Stimulates Hair Follicle Stem Cells for Robust Hair Growthhttps://practicaldermatology.com/news/osteopontin-potently-stimulates-hair-follicle-stem-cells-for-robust-hair-growth/2461802/Do hairy moles hold the secret to understanding hair growth? Maybe, according to research published in the June 21, 2023 issue of Nature. Using a mouse model, researchers tracked the activity of ha
- National Rosacea Society Offers New Seal of Acceptancehttps://practicaldermatology.com/news/national-rosacea-society-offers-new-seal-of-acceptance/2461801/The National Rosacea Society is launching a Seal of Acceptance program to identify skin care and cosmetic products that may be suitable for people with rosacea. “One of the most common requests the Society receives from rosacea patients is for info
- Cedric Burg Named New COO at Innovadermhttps://practicaldermatology.com/news/cedric-burg-named-new-coo-at-innovaderm/2461798/Cedric Burg is Innovaderm’s new Chief Operating Officer. Mr. Burg’s new role entails the management of Innovaderm’s global operations in Canada, through the close collaboration between department heads while overseeing most of Innovaderm’s activi
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Zydus Lifesciences Scores FDA Nod for Generic Acne Drughttps://practicaldermatology.com/news/zydus-lifesciences-scores-fda-nod-for-generic-acne-drug/2461791/The U.S. Food and Drug Administration (FDA) has given its nod to Zydus Lifesciences’ generic antibiotic minocycline hydrochloride extended-release tablets for the treatment of moderate to severe acne in 55 mg, 65 mg, and 115 mg doses, the Company reports. Minocycline hyd
- Cutera's AviClear Scores FDA Nod as Long-Term Acne Treatmenthttps://practicaldermatology.com/news/cuteras-aviclear-scores-fda-nod-as-long-term-acne-treatment/2461784/The U.S. Food and Drug Administration (FDA) has cleared AviClear as a long-term treatment for mild to severe inflammatory acne vulgaris. Cutera’s AviClear initially received FDA clearance for treating acne in March 2022. Now, the FDA has cleared the device for the long
- Belotero Balance (+) Restores Volume to Under-eye Hollowshttps://practicaldermatology.com/news/belotero-balance-restores-volume-to-under-eye-hollows/2461782/Belotero Balance® (+) corrects volume loss in the infraorbital hollow area, according to new data from Merz Aesthetics. Merz Aesthetics will submit these data as part of a supplemental Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) this
- And the Winners Are…Botox Cosmetic Announces the Winners of the IFundWomen Grant Programhttps://practicaldermatology.com/news/and-the-winners-arebotox-cosmetic-announces-the-winners-of-the-ifundwomen-grant-program/2461779/Twenty female entrepreneurs will receive funding and mentorship through Allergan’s BOTOX Cosmetic and IFundWomen grant program. "There were so many remarkable applications that featured thoughtful business solutions," says Carrie Strom, President, Global Aller
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs &am